These studies indicate the potential for utilizing DN T cells as future immune therapeutic targets (potentially utilizing IL7, IL2 or a combination of IL2/IL7 therapy) to increase their levels and/or function during pathogenic HIV infection as one component of a functional cure to inhibit progression to clinical disease and AIDS. The gene discussed is IL2; the disease is HIV infectious disease.